Claudia Riedl
Fortune : 1 470 $ au 31/05/2026
Fortune : 1 470 $ au 31/05/2026
Dr. Claudia Riedl is an Independent Non-Executive Director at Vivoryon Therapeutics NV.
She is on the Board of Directors at Vivoryon Therapeutics NV.
Dr. Riedl was previously employed as a Head-Corporate Communications & Investor Relations by MorphoSys AG.
She received her doctorate degree from Technische Universität München.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2025 | 1 000 ( 0 % ) | 1 470 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Directeur/Membre du Conseil | 01/01/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| MORPHOSYS AG | Public Communications Contact | 01/01/2016 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 3 |
|---|---|
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Technische Universität München
Technische Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivoryon Therapeutics NV
Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national